Clinical Trial Search

Primary: Efficacy of Toremifene in the Prevention of Prostate Cancer in Men With High Grade Prostatic Intraepithelial Neoplasia (PIN) — 54.9; 59.5 % of participants cancer-free…

Primary: Oral Cancer-free Survival — NA; 6.7 Months

Primary: Rate of Progression to Prostate Cancer (PCa) — 4; 6 participants

Primary: Percentage of Subjects That Experienced Infection, Urinary Retention or Bleeding Requiring Intervention Within 7 Days of Biopsy Based on Transrectal Ultrasound Guided…

Primary: Nonfunctioning and Malignant Pancreatic Endocrine Neoplasms — 28; 12; 22; 18 participants

Primary: Change in International Prostate Symptom Scale (IPSS) of Lower Urinary Tract Symptoms From Baseline to 3 Months (Total Score at 3 Months Minus Total Score at Baseline)…

Primary: Number of Subjects With GI Bleeding — 1; 1 participants

Primary: Number of Participants With Bladder or Rectal Injury — 0 Participants

Primary: Assess the Ability of 99mTc-MIP-1404 to Detect Prostate Cancer Within the Prostate Gland. — 94.2 % sensitivity

Primary: Number of Participants With Clinically Significant Prostate Cancer — 6; 6 Participants

Primary: Number of Participants With Treatment Emergent Adverse Events (Safety and Tolerability) — 3; 2; 6; 3 Participants

Primary: Number of Participants With Dose Limiting Toxicities (Phase I and Safety Run-In) — 0; 0 Participants

Primary: Number of Participants With Overall Response as Determined by iRECIST — 1; 1; 3; 9 Participants

Primary: Detected Intraepithelial Neoplasia — 0.2 Number of detected IN

Primary: Number of Adverse Events Reported — 7 adverse events

Primary: Number of Participants With Treatment Emergent Adverse Events (Safety and Tolerability) — 3; 3; 3; 9 Participants

Primary: Number of Participants With Biochemical Failure at 5 Years — 0; 30 Participants

Primary: Histologic Regression — 40; 34.1 percentage of participants

Primary: The Primary Objective is to Evaluate the Safety of Prostate Artery Embolization (PAE) for the Treatment of Lower Urinary Tract Symptoms (LUTS) Attributed to Benign…

Primary: Number of Participants With Adverse Events — 3 Participants

Primary: Number of Participants Who Had Biopsies With True Positives Between Biopsy Tissue and Intraprostatic MRI — 2 Participants

Primary: Prostate-Specific Antigen (PSA) Response — 14 participants

Primary: Time to Disease Progression — 15.2 weeks

Primary: Sensitivity of PSMA-PET and MRI Imaging Preoperatively for Predicting Extra-prostatic Extension — 86; 57 percentage — p=<0.05

Primary: Change in the Number of Infiltrating CD3+ T Cells Within the Prostate Tissue Between the Biopsy and the Post-RP Tissue Specimens in Each Subject — 2.33; 2.03; 1.98; 6.39…

Primary: Mean Change in IPSS Score — -11.4 units on a scale

Primary: Compare the Biodistribution of 11C-acetate Positron Emission Tomography (PET)/Computed Tomography (CT) Imaging in Tumor and Non Tumorous Regions of the Prostate — 4.4…

Primary: Keyword Description of Each Biopsy Sample — 89 percentage significant cancers detected

Primary: Presence of Carcinoma of the Prostate as Measured by Biopsy — 48; 49 participants — p=0.73

Primary: Incidence of HPV 6/11/16/18-related Cervical Intraepithelial Neoplasia (CIN)(Any Grade), Adenocarcinoma In Situ (AIS) or Cervical Cancer — 0; 1.2 incidence rate per 100…